Drug-Eluting, Stent

Mordor Intelligence Private Limited United States of America United Kingdom

27.08.2025 - 16:01:30

Drug-Eluting Stent Market to Hit USD 9.47 Billion by 2030, Says Mordor Intelligence

Peripheral Stents Market is projected to rise from USD 5.75 billion in 2025 to USD 8.19 billion by 2030, growing at a CAGR of 7.3%. This momentum is fueled by the increasing prevalence of peripheral artery disease (PAD), steady advances in stent technology, and the wider adoption of minimally invasive procedures that help shorten recovery times. Longer life expectancy, expanding procedure volumes, and the rise of ambulatory surgical centers (ASCs) further support demand.

About Mordor Intelligence: 

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals. 

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics. 

For media inquiries or further information, please contact:  
media@mordorintelligence.com  
Mordor Intelligence Private Limited  
https://www.mordorintelligence.com/  

Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/drug-eluting-stent-market-to-hit-usd-9-47-billion-by-2030--says-mordor-intelligence-302538821.html

@ prnewswire.co.uk